Alpha Cognition vs Keros Therapeutics
Keros Therapeutics is the larger business, with $244m of revenue in fiscal 2025 against $10.2m for Alpha Cognition (23.9 times as much). Keros Therapeutics kept more of each dollar of sales as profit: a net margin of 35.7% against -202.2%. Alpha Cognition carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Alpha CognitionACOG, 2025 | Keros TherapeuticsKROS, 2025 |
|---|---|---|
| Revenue | $10.2m | $244m |
| Revenue growth | — | 6769.4% |
| Net income | −$20.7m | $87.0m |
| Operating margin | -221.7% | 27.7% |
| Net margin | -202.2% | 35.7% |
| Return on equity | -33.1% | 19.9% |
| Free cash flow | −$20.7m | $106m |
| Cash | $66.0m | $287m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $375m |
| Employees | 71 | 78 |
| Market value | $179m | $215m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 60 buys, 0 sales | 6 buys, 12 sales |